Odyssey Therapeutics, Inc.

ODTX

$26.90

+1.89%

N/A+$0.50

Healthcare

Biotechnology

NASDAQ

Active Trading

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse ...

Financial Highlights of ODTX

Profitability trend

Latest / TTM · 2 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-10.55x

n/a

Debt / Equity

0.06

n/a

Current Ratio

11.36

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 2 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-10.55x

Debt / Equity

0.06

Profitability

Profitability table

Metric	2025	2026
Gross MarginGross profit as a percentage of revenue.	100.0%	—
Operating MarginOperating income as a percentage of revenue.	-5415.2%	—
Net MarginNet income as a percentage of revenue.	-4994.9%	—
EBITDA MarginEBITDA divided by revenue.	-4860.4%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-5026.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2025	2026
Current RatioCurrent assets divided by current liabilities.	7.20	—
Quick RatioLiquid assets divided by current liabilities.	7.20	—
Cash RatioCash and equivalents divided by current liabilities.	1.57	—
Debt / AssetsDebt as a share of total assets.	10.0%	—
Debt / EquityDebt compared with shareholder equity.	-0.06	—

Operating efficiency

Operating efficiency table

Metric	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.01x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-3.05x	—
P/B RatioPrice paid for each dollar of book value.	-0.93x	—
P/S RatioPrice paid for each dollar of sales.	152.07x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-3.46x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	—

Supply Chain of ODTX

RELATIONS

Upstream

Terray TherapeuticsMiracle ML (Miracle)Small Molecule CDMO (Contract Development & Manufacturing Organization)Clinical CRO Partner(s)Thermo Fisher Scientific Inc.NYSE:TMO Danaher CorporationNYSE:DHR Agilent Technologies Inc.NYSE:AMerck KGaA (MilliporeSigma)XETR:MRKCharles River Laboratories International Inc.NYSE:CRL

Downstream

Janssen Pharmaceutica NV (Johnson & Johnson)NYSE:JNJ Pfizer Inc.NYSE:PFETerray Therapeutics

Proxies

Prometheus Biosciences (acquired by Merck)UnconfirmedTG Therapeutics Inc.NASDAQ:TGTX Ventyx Biosciences Inc.NASDAQ:VTYXLandos Biopharma (acquired by AbbVie)Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer